Wird geladen...
Overcoming acquired resistance to cetuximab by dual targeting HER family receptors with antibody-based therapy
BACKGROUND: Cetuximab, an anti-EGFR monoclonal antibody, is used to treat several cancers. However, many patients who initially respond to cetuximab acquire resistance. To examine mechanisms of acquired resistance, we developed a series of cetuximab-resistant (Ctx(R)) clones derived from the cetuxim...
Gespeichert in:
| Veröffentlicht in: | Mol Cancer |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
BioMed Central
2014
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4283113/ https://ncbi.nlm.nih.gov/pubmed/25344208 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1476-4598-13-242 |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|